▼ -2.18% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $44.21, with a high forecast of $54.00 and a low forecast of $12.50. The average price target represents a -2.18% upside from the last price of $45.20.
The current consensus among 7 polled investment analysts is to buy stock in Replimune Group.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.